[en] Several entities have been carefully investigated for the symptomatic and structural management of osteoarthritis (OA). The most compelling evidence of a potential for inhibiting the structural progression of OA has been obtained with glucosamine sulfate, while some preliminary results also suggest that other compounds could be used in the same indication. At any rate, several medications have clearly demonstrated a symptomatic action, mainly in OA of the lower limbs, including pain relief and improvement of functional disability. An important issue is that all conclusive studies with such chemical entities resulted from the use of prescription medicines and not over-the-counter or nutriceutical supplements.
Disciplines :
Public health, health care sciences & services Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Henrotin, Yves ; Université de Liège - ULiège > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Language :
English
Title :
New perspectives in the management of osteoarthritis. Structure modification: Facts or fantasy?
Reginster, J.Y., The prevalence and burden of arthritis (2002) Rheumatology, 41, pp. 3-6
(1998) Points to Consider on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis, , http://www.emea.eu.int/pdfs/human/ewp/078497en.pdf, European Agency for the Evaluation of Medicinal Products
(1999) Guidance for Industry - Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis, , http://www.fda.gov/cder/guidance/2199dft.htm
Dougados, M., Devogelaer, J.P., Annefeldt, M., Recommendations for the registration of drugs used in the treatment of osteoarthritis (1996) Ann Rheum Dis, 55, pp. 552-557
Hardingham, T.E., Chondroitin sulfate and joint disease (1998) Osteoarthritis Cartilage, 6, pp. 3-5
Hardingham, T.E., Fosang, A.J., Proteoglycans: Many forms, many functions (1992) FASEB J, 6, pp. 861-870
Hardingham, T.E., Bayliss, M.T., Proteoglycans of articular cartilage: Changes in ageing and in joint disease (1991) Semin Arthritis Rheum, 20, pp. 12-33
Bassleer, C.T., Comban, J.P.A., Bougaret, S., Effects of chondroitin sulfate and IL-1 beta on human articular chondrocytes cultivated in clusters (1998) Osteoarthritis Cartilage, 6, pp. 196-204
Reveliere, D., Mentz, F., Merle-Beral, H., Protective effect of chondroitin 4 & 6 sulfate on apoptosis of rabbit articular chondrocytes: Preliminary results (1999) New Approaches in OA: Chondroitin Sulfate (CS 4 & 6) Not Just a Symptomatic Treatment, pp. 15-20. , Mautone G, Tajana E, Rovati S, Vacher D, editors. Zurich: Litera Rheumatologica 24, EULAR
Uebelhart, D., Eugene, J.M., Thonar, A., Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit (1998) Osteoarthritis Cartilage, 6, pp. 6-13
Bourgeois, P., Chales, G., Dehais, J., Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg vs placebo (1998) Osteoarthritis Cartilage, 6, pp. 25-30
Morreale, P., Manopulo, R., Galati, M., Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis (1996) J Rheumatol, 23, pp. 1385-1391
Pavelka, K., Manopulo, R., Bucsi, L., Double-blind, dose-effect study of oral chondroitin 4 & 6 sulfate 1200 mg, 800 mg, 200 mg and placebo in the treatment of knee osteoarthritis (1999) New Approaches in OA: Chondroitin Sulfate (CS 4 & 6) Not Just a Symptomatic Treatment, pp. 15-20. , Mautone G, Tajana E, Rovati S, Vacher D, editors. Zurich: Litera Rheumatologica 24, EULAR
Bucsi, L., Poor, G., Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis (1998) Osteoarthritis Cartilage, 6, pp. 31-36
Malaise, M., Marcolongo, R., Uebelhart, D., Efficacy and tolerability of 800 mg oral chondroitin 4 & 6 sulfate in the treatment of knee osteoarthritis: A randomised, double-blind, multicentre study versus placebo (1999) New Approaches in OA: Chondroitin Sulfate (CS 4 & 6) Not Just a Symptomatic Treatment, pp. 15-20. , Mautone G, Tajana E, Rovati S, Vacher D, editors. Zurich: Litera Rheumatologica 24, EULAR
Michel, B., Vignon, E., De Vathaire, F., Oral chondroitin sulphate in knee OA patients: Radiographic outcomes of a 2-year prospective study (2001) Osteoarthritis Cartilage, 9, pp. S68
Setnikar, I., Cereda, R., Pacine, M.A., Antireactive properties of glucosamine sulfate (1991) Arzneimittelforschung, 41, pp. 157-161
Jimenez, S.A., Dodge, G.R., The effects of glucosamine sulfate (GSO4) on human chondrocyte gene expression (1997) Osteoarthritis Cartilage, 5 (SUPPL. A), p. 72
Dodge, G.R., Hawkins, J.F., Jimenez, S.A., Modulation of aggrecan, MMP1 and MMP3 productions by glucosamine sulfate in cultured human osteoarthritis articular chondrocytes (1999) Arthritis Rheum, 42 (SUPPL.), pp. S253
Basleer, C., Rovati, L., Franchimont, P., Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritis articular cartilage in vitro (1998) Osteoarthritis Cartilage, 6, pp. 427-434
Sandy, J.D., Gamett, D., Thompson, V., Chondrocyte-mediated catabolism of aggrecan: Aggrecanase-dependent cleavage induced by IL-1 or retinoic acid can be inhibited by glucosamine (1998) Biochem J, 355, pp. 59-66
Shikhman, A., Alaaeddine, N., Lotz La Jolla, M.K., N-acetylglucosamine prevents IL-1 mediated activation of chondrocytes (1991) Arthritis Rheum, 42 (SUPPL.), pp. S381
Abelda, S.M., Buck, C.A., Integrins and other cell adhesion molecules (1990) FASEB J, 4, pp. 2868-2880
Piperno, M., Reboul, P., Hellio Le Graverand, M.P., Glucosamine sulfate modulates dysregulated activities of human osteoarthritis chondrocytes in vitro (2000) Osteoarthritis Cartilage, 8, pp. 207-212
Conrozier, T., Mathieu, P., Piperno, M., Glucosamine sulfate significantly reduced cartilage destruction in a rabbit model of osteoarthritis [abstract] (1998) Arthritis Rheum, 41 (SUPPL.), p. 147
Reichelt, A., Förster, K.K., Fischer, M., Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee (1994) Arzneimittelforschung, 44, pp. 75-80
Setnikar, I., Palumbo, R., Canali, S., Pharmacokinetics of glucosamine in man (1993) Arzneimittelforschung, 43, pp. 1109-1113
Noack, W., Fischer, M., Förster, K.K., Glucosamine sulfate in osteoarthritis of the knee (1994) Osteoarthritis Cartilage, 2, pp. 51-59
Rovati, L.C., Clinical development of glucosamine sulfate as selective drug in osteoarthritis (1997) Rheumatology Europe, 26, p. 70
Houpt, J.B., McMillan, R., Wein, C., Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee (1999) J Rheumatol, 26, pp. 2423-2430
Rovati, L.C., Clinical efficacy of glucosamine sulfate in osteoarthritis of the spine (1993) Rev Esp Reumatol, 20, p. 325
Fassbender, H.M., Bach, G.L., Haase, W., Glucosamine sulfate compared to Ibu in osteoarthritis of the knee (1994) Osteoarthritis Cartilage, 2, pp. 61-69
Qiu, G.X., Gao, S.N., Giacovelli, G., Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis (1998) Arzneimittelforschung, 48, pp. 469-474
Rovati, L.C., The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: Current data and perspectives (1997) Osteoarthritis Cartilage, 5 (SUPPL. A), p. 72
Reginster, J.Y., Deroisy, R., Rovati, L., Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial (2001) Lancet, 357, pp. 251-256
Pavelka, K., Gatterova, J., Olejarova, M., Machacek, S., Giacovelli, G., Rovati, L., Glucosamine sulfate delays progression of knee osteoarthritis: A 3-year, randomised, placebo-controlled, double-blind study (2002) Arch Intern Med, 162, pp. 2113-2123
Towheed, T.E., Anastassiades, T.P., Glucosamine therapy for osteoarthritis (1999) J Rheumatol, 26, pp. 2294-2297
Tapadinhas, M.J., Rivera, I.C., Bignamini, A.A., Oral glucosamine sulphate in the management of arthrosis
report on a multi-centre open investigation in Portugal (1982) Pharmacotherapeutica, 3, pp. 157-168
Adams, M.E., Hype about glucosamine (1999) Lancet, 354, pp. 353-354
Rovati, L.C., Annefeld, M., Giacovelli, G., Glucosamine in osteoarthritis (1999) Lancet, 4, p. 1640
Robert, A.M., Miskulin, M., Godeau, G., Pharmacologie du tissu conjonctif. Action des insaponifiables d'avocat et de soja sur le métabolisme de la matrice intercellulaire (1975) Gaz Med Fr, 82, pp. 2-6
Dupurrat, B., Lamberton, J.N., Le traitement des sclérodermies par les insaponifiables d'huiles végétales (1970) Arch Belg Dermat Symphil, 26, pp. 271-277
Kerbel, B., Clergeau-Guerithault, S., Brion, M., A scanning electron miscroscope study of experimental periodontal disease. Its induction and inhibition (1975) J Periodontol, 46, pp. 27-35
Mauviel, A., Daireaux, M., Hartmann, D.J., Effects of unsaponifiable extracts of avocado/soy beans (PIAS) on the production of collagen by cultures of synoviocytes, articular chondrocytes and skin fibroblasts (1989) Rev Rhum Mal Osteoartic, 56, pp. 207-211
Mauviel, A., Loyau, G., Pujol, J.P., Effect of unsaponifiable extracts of avocado and soybean (Piascledine) on the collagenolytic action of cultures of human rheumatoid synoviocytes and rabbit articular chondrocytes treated with interleukin-1 (1991) Rev Rhum Mal Osteoartic, 58, pp. 241-245
Henrotin, Y.E., Labasse, A.H., Jaspar, J.M., Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes (1998) Clin Rheumatol, 17, pp. 31-39
Boumediene, K., Felisaz, N., Bogdanowicz, P., Avocado/soya unsaponifiables enhance the expression of transforming growth factor beta 1 and beta 2 in cultured articular chondrocytes (1999) Arthritis Rheum, 42, pp. 148-156
Blotman, F., Maheu, E., Wulwik, A., Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial (1997) Rev Rhum Engl Ed, 64, pp. 825-834
Lesquene, M., Maheu, E., Cadet, C., Dreiser, R.-L., Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip (2002) Arthritis Rheum, 47, pp. 50-58
Dougados, M., Nguyen, M., Berdah, L., Mazières, B., Vignon, E., Lequesne, M., Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis (2001) Arthritis Rheum, 44, pp. 2539-2547
Sharma, J.N., Srivastava, K.C., Gand, E.K., Suppressive effects of eugenol and ginger oil on arthritic rats (1994) Pharmacology, 49, pp. 314-318
Srivastava, K.C., Mustafa, T., Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders (1992) Med Hypotheses, 39, pp. 342-348
Bliddal, H., Rosetzsky, A., Weidner, M.S., A randomized, placebo-controlled, cross-over study of ginger extracts and Ibuprofen in osteoarthritis (2000) Osteoarthritis Cartilage, 8, pp. 9-12
Altman, R.D., Marcussen, K., Sigwart, F.N., Christensen, F.N., Extract of zingiber officinale (ginger) and alpinia galanga in osteoarthritis (2000) Ann Rheum Dis, 59, p. 55
Henrotin, Y., Labasse, A., Zheng, S.X., Strontium ranelate increases cartilage matrix formation (2001) J Bone Miner Res, 16, pp. 299-308
Frizziero, L., Govoni, E., Bacchini, P., Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: Clinical and morphological study (1998) Clin Exp Rheumatol, 16, pp. 441-449
